Integrated Advisors Network’s CRISPR Therapeutics CRSP Stock Holding History

Integrated Advisors Network’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,261	Closed	-$211K	–	737
2025 Q3	$211K	Buy	+3,261	New	+$187K	0.01%	738
2024 Q3	–	Sell	-5,430	Closed	-$293K	–	713
2024 Q2	$293K	Sell	5,430 -3,378	-38%	-$195K	0.02%	571
2024 Q1	$600K	Buy	8,808 +1,105	+14%	+$79.1K	0.03%	414
2023 Q4	$482K	Buy	7,703 +500	+7%	+$27.6K	0.03%	443
2023 Q3	$327K	Buy	+7,203	New	+$372K	0.02%	520

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integrated Advisors Network's CRSP Position: Q4 2025 in Review

Integrated Advisors Network sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,261 shares — an estimated $211K sold.

Integrated Advisors Network first reported a position in CRSP in Q3 2023 and held it in 5 quarters. The position peaked at $600K in Q1 2024. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Integrated Advisors Network reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Integrated Advisors Network sold 3,261 CRISPR Therapeutics shares in Q4 2025, an estimated $211K.
Integrated Advisors Network first reported a position in CRISPR Therapeutics in Q3 2023 and held it in 5 quarters.
Integrated Advisors Network's CRISPR Therapeutics position peaked at $600K in Q1 2024.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Integrated Advisors Network's 13F filing for Q4 2025, filed 17 Feb 2026.